<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330746</url>
  </required_header>
  <id_info>
    <org_study_id>CALC-1</org_study_id>
    <secondary_id>2004-002811-98</secondary_id>
    <nct_id>NCT00330746</nct_id>
  </id_info>
  <brief_title>CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer</brief_title>
  <acronym>CALC-1</acronym>
  <official_title>Randomized Phase II Study of Cetuximab in Combination With Gemcitabine or Gemcitabine Followed by Cetuximab in Advanced Non Small-cell Lung Cancer Patients Who Are Not Candidates for Platinum Based Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to select the more promising method of combining cetuximab with
      gemcitabine for treating patients with advanced non small-cell lung cancer, who are not
      candidates for platinum based therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard treatment for advanced non small cell lung cancer (NSCLC) is combination
      chemotherapy with cisplatin or carboplatin. Due to its toxicity, this therapy may not be
      suited for certain patients including the elderly, those whose general condition is poor.
      Combining chemotherapy with a biologic agent (&quot;targeted therapy&quot;) is a new strategy being
      evaluated for the treatment of NSCLC, and cetuximab is one of the drugs that has shown
      promise for its activity and tolerability. This study aims to determine the more promising of
      2 methods of combining gemcitabine with cetuximab (in combination vs. sequential
      administration), in two groups of patients who are not candidates for combination platinum
      based chemotherapy: patients under age 70 with performance status 2 (expected enrollment 42)
      , and patients over age 70 (expected enrollment 58).

      Patients will be randomly assigned to one of two treatment arms:

        -  Arm A: Cetuximab + Gemcitabine:

             -  Cetuximab given intravenously weekly AND

             -  Gemcitabine given intravenously for a maximum of 6 cycles (on days 1 and 8 of each
                3 week cycle)

        -  Arm B: Gemcitabine followed by Cetuximab:

             -  Gemcitabine given intravenously for a maximum of 6 cycles (on days 1 and 8 of each
                3 week cycle) THEN

             -  Cetuximab given intravenously weekly

      In Arm B, Cetuximab is administered as maintenance therapy when there has been an objective
      response to chemotherapy, or as second line therapy in patients who had disease progression
      during chemotherapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>one year survival rate</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic role of cetuximab associated skin toxicities</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Advanced Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cetuximab and gemcitabine combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemcitabine followed by cetuximab (sequential)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>400 mg/m2 first dose followed by 250 mg/m2 weekly</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Age &gt; 18

          -  Histological diagnosis of non small-cell lung cancer (NSCLC)

          -  Stage III B or Stage IV disease

          -  Contraindications to platinum based therapy (age &gt; 70 or age &lt; 70 with ECOG
             performance status 2)

          -  At least one site of metastasis (target or non-target)

          -  Life expectancy of at least 3 months

          -  ECOG &lt;3

          -  Neutrophils &gt; 1500/mm3, platelets &gt; 100,000/mm3, hemoglobin &gt; 9g/dl

          -  Bilirubin &lt; 1.5 x the upper normal limit

          -  SGOT and SGPT &lt; 2.5 x the upper normal limits (&lt; 5 x the upper normal limit in the
             presence of hepatic metastasis)

          -  Creatinine &lt; 1.5 x the upper normal limit

          -  Adequate method of contraception (male and female), when there is risk of conception.

        Exclusion Criteria:

          -  Symptomatic cerebral metastasis

          -  Previous chemotherapy for advanced disease

          -  Adjuvant chemotherapy within the previous 6 months

          -  Radiation therapy within previous 4 weeks

          -  Any experimental drug therapy within the previous 4 weeks

          -  Previous exposure to monoclonal antibodies, signal transduction inhibitors or EGFR
             targeting therapy

          -  Clinically relevant cardiopathy or myocardial infarct within the last 12 months

          -  Acute or subacute intestinal occlusion or history of inflammatory bowel disease

          -  Known allergy to one or more of the experimental treatments

          -  Known alcohol or substance abuse

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the patient to complete the study or give informed consent

          -  Pregnant or breastfeeding females

          -  History of malignant neoplasm within the previous 5 years (not including non-melanoma
             skin carcinoma and in-situ carcinoma of the uterine cervix, provided they are being
             adequately treated)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesare Gridelli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>S.G. Moscati Hopital, Avellino, Italy, Division of Medical Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fortunato Ciardiello, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Univesity of Naples, Italy; Chair Medical Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute Naples, Italy; Director Clinical Trials Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second University of Naples, Italy; Chair of Medical Statistics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Sanitaria S. Giuseppe Moscati</name>
      <address>
        <city>Monteforte Irpino</city>
        <state>AV</state>
        <zip>83024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A. Cardarelli</name>
      <address>
        <city>Campobasso</city>
        <state>CB</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Chieti</name>
      <address>
        <city>Chieti</city>
        <state>CH</state>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto di Frosinone</name>
      <address>
        <city>Frosinone</city>
        <state>FR</state>
        <zip>03031</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Villa Scassi</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Gaeta</name>
      <address>
        <city>Gaeta</city>
        <state>LT</state>
        <zip>04024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico G. Martino</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98148</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giuseppe</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico S. Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Paolo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Gerado</name>
      <address>
        <city>Monza</city>
        <state>MI</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera C. Poma</name>
      <address>
        <city>Mantova</city>
        <state>MN</state>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Prato</name>
      <address>
        <city>Prato</city>
        <state>PO</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Croce</name>
      <address>
        <city>Fano</city>
        <state>PS</state>
        <zip>61032</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Salvatore</name>
      <address>
        <city>Pesaro</city>
        <state>PU</state>
        <zip>61100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Umberto I</name>
      <address>
        <city>Nocera Inferiore</city>
        <state>SA</state>
        <zip>84014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale E. Morelli</name>
      <address>
        <city>Sondalo</city>
        <state>SO</state>
        <zip>23039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliaro Alto Gardo e Ledro</name>
      <address>
        <city>Arco</city>
        <state>TN</state>
        <zip>38062</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Chiara</name>
      <address>
        <city>Trento</city>
        <state>TN</state>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Busto Arsizio</name>
      <address>
        <city>Saronno</city>
        <state>VA</state>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncologia Medica, U.S.L.L. 13</name>
      <address>
        <city>Noale</city>
        <state>VE</state>
        <zip>30033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second University of Naples</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Gridelli D, Mencoboni M, Carrozza F, Viganò MG, Gebbia V, Verusio C, Maione P, Gallo C, Perrone F, Ciardiello F. Cetuximab (C) and gemcitabine (G) in elderly or adult PS2 advanced non small-cell lung cancer (NSCLC) patients (pts): The CALC1 randomised phase II trials. Journal of Clinical Oncology 26: 2008 (May 20 suppl; abstr 8117)</citation>
  </results_reference>
  <results_reference>
    <citation>Gridelli C, Morabito A, Gebbia V, Mencoboni M, Carrozza F, Viganò MG, Verusio C, Bollina R, Mattioli R, Valerio MR, Valmadre G, Maione P, Rossi A, Cascone T, Morgillo F, Di Maio M, Piccirillo MC, Gallo C, Perrone F, Ciardiello F. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer. 2010 Jan;67(1):86-92. doi: 10.1016/j.lungcan.2009.03.021.</citation>
    <PMID>19380175</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2006</study_first_submitted>
  <study_first_submitted_qc>May 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2006</study_first_posted>
  <last_update_submitted>May 17, 2012</last_update_submitted>
  <last_update_submitted_qc>May 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>elderly</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>combination therapy</keyword>
  <keyword>sequential therapy</keyword>
  <keyword>randomized phase II</keyword>
  <keyword>one year survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

